SAN DIEGO--(BUSINESS WIRE)--AltheaDx, Inc. today announced the launch of its CLIA-validated, next-generation sequencing (NGS) assay, AltheaDx Oncology Panel™ (AOP™50), designed for multiple drug and companion diagnostic development programs.
Based on Thermo Fisher Scientific’s Oncomine Focus Assay, the AOP™50 Assay allows concurrent analysis of DNA and RNA from solid tumors, enabling sequencing of 35 hotspot genes and 23 fusion genes in a single workflow on the Ion PGM System. With the increasing importance of genetic translocations in oncology, the AOP™50 Assay also enables gene fusion transcript detection and reduces the complexity of performing alternate fusion detection methods such as fluorescence in situ hybridization (FISH).
Based on Thermo Fisher Scientific’s Oncomine Focus Assay, the AOP™50 Assay allows concurrent analysis of DNA and RNA from solid tumors, enabling sequencing of 35 hotspot genes and 23 fusion genes in a single workflow on the Ion PGM System. With the increasing importance of genetic translocations in oncology, the AOP™50 Assay also enables gene fusion transcript detection and reduces the complexity of performing alternate fusion detection methods such as fluorescence in situ hybridization (FISH).
